| | National Quality Forum | | | | |
|---|--|---------------|--|--|--|
| | Comments on Ad Hoc Review of Safe Practice #22 Specification | | | | |
| # | Organization Contact | Topic | Comment | | |
| | Nancy Moureau, PICC Excellence | Justification | Adams D, Quayum M, Worthington T, Lambert P, Elliot T. Evaluation of a 2% chlorhexidine gluconate in 70% isopropyl alcohol skin disinfectant. J Hosp Infect. 2005;61:287–290. Atherton SL, Tjoelker RC. Evidence based fact sheet: an effective method for implementing change. Am J Infect Control . 2006;34:E51. Presented at: 33rd Annual Educational Conference and International Meeting of the Association for Professionals in Infection Control and Epidemiology: June 11-15, 2006; Tampa, Florida. Abstract 7-53. Render ML, Brungs S, et al. Evidence-based practice to reduce central line infections. Jt Comm J Qual Patient Saf. 2006 May;32(5):253-60. Carpenter D. Prevent nosocomial infections at the start. Mater Manag Health Care. 2006;15:46–48. Darouiche R, Wall M Jr, Itani M, et al. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med. 2010;362:18-26. Fletcher N, Sofianos D, Brantling Berkes M, Obremskey WT. Prevention of Perioperative Infection. J Bone Joint Surg Am . 2007;89:1601-1618. Florman S. Nichols RL. Tulane Abdominal Transplant Institute, Tulane University School of Medicine, New Orleans, Louisiana Department of Surgery. Tulane University School of Medicine, New Orleans, Louisiana Department of Surgery. Tulane University School of Medicine, New Orleans, Louisiana Department of Surgery. Tulane University School of Medicine, New Orleans, Louisiana Department of Surgery. Tulane University School of Medicine, New Orleans, Louisiana Department of Surgery. Tulane University School of Medicine, New Orleans, Louisiana. Current Approaches for the Prevention of Surgical Site Infections. Am J Infect Dis . 2007;3(1): 51-61. Garcia R, Hibbard JS. Antimicrobial activity of a recently approved chlorhexidine-isopropyl alcohol antiseptic And Many more | | |

| # | Organization Contact | Topic | Comment |
|----|--|---------------|--|
| 9 | Nancy Moureau, PICC Excellence | Justification | Because of its effectiveness and the increasing evidence of its superior performance compared to other antiseptics, chlorhexidine should be considered as the default skin prep. Since 2002, the Centers for Disease Control has recommended 2% chlorhexidine with 70% isopropyl alcohol as the skin antiseptic of choice prior to the insertion of vascular catheters. It has yet to release a statement for pre-surgical skin preparation. More recently, the National Quality Forum, in its Safe Practices 22: Surgical Site Infection Prevention, calls for the use of a chlorhexidine and isopropyl alcohol solution as a skin prep prior to surgical procedures. Chlorhexidine and alcohol are now considered the most recommended prepping agent for the United States and around the world. These recommendations were recently bolstered by a study published in the January 7 issue of the New England Journal of Medicine. In a multi-center study with 849 surgical patients, Darouiche and colleagues found that patients who were prepped with chlorhexidine and alcohol had nearly half as many surgical site infections (9.5%) compared to those prepped with povidone-iodine (16.1%). This study follows a related study from 2005 in which researchers at the University of California, San Diego analyzed culture specimens gathered from foot and ankle surgery patients who were prepped with chlorhexidine, iodine-alcohol or chloroxylenol. |
| 10 | Kathy Lemmon, DuBois Regional Medical Center | Justification | After implementation of ChloraPrep (CHG/Alcohol), we have seen a dramatic decline in SSIs. We have had zero adverse effects from use of ChloraPrep. CHG is a superior disinfecting agent and we will continue to use it for most surgical preps. |
| 12 | Linda Cheshier, Ottawa Regional Hospital and Healthcare Center | Justification | Duraprep is marketed as a 1 step skin prep device that eliminates the need for a separate paint with alcohol. The studies conducted comparing Chloraprep to Duraprep were valid. Chloraprep is a combination solution of prep agents that is effective in lowering SSI rates. The one step prep by Chloraprep vs Duraprep were compared equally and fairly. I recommend that if a one step prep is supported and endorsed under Safe Practice 22, it would be for chlorhexidine and alcohol in a one step application method. |

| # | Organization Contact | Topic | Comment |
|----|--|---------------|--|
| 13 | nikolaus gravenstein, university of florida college of medicine | Justification | There is no perfect universal skin prep solution; but given that disinfection is imperfect and that therefore the remaining microbes lie in wait to muliply it is difficult to not favor a chlorhexidine containing solution with a much more enduring effect and one that is not interfered with by proteins in blood as is encountered during surgical procedures as compared to an iodine based prep. no doubt in both cases the alcoholic component is relevant. re the studies neither the 3m cited ones nor the chg advocating ones are perfectly comparable but on balance it is very difficult to compellingly argue against chg-ipa as the preferred skin prep solution for eligible operative sites. Other solutions should certainly be allowed and accomodated. The many specialty societies and organizations that have looked at the preferred preferred preprocedure disinfecting skin prep have i think overwhelmingly and independently also concluded that chlorhexidine/ alcohol is preferred- even when it comes for example to neuraxial access (American Society of Regional Anesthesia) |
| 15 | Debby Ohayon, kaleidahealth | Justification | Based on the evidence and my experience 2%CHG and alcohol is a superior patient prep solution compared to iodine based solutions. It provides facilities with a quick bacterial kill as well as prolonged persistence which has shown to be an integral part in lowering SSI rates. |
| 18 | Kevin Bussiere, Sentara Leigh Hospital | Justification | I believe that the NQF is justified in making recommendations based upon the existing research that is cureently available. The current research shows that the combination of CHG and alcohol has an effective antisepsis superior to any antisepsis that has= been tested in a similar clinical trial. It is the mechanism of the CHG/Alcohol which is superior. Iodopurs have too narrow a function range with limited residual effect. PCMX is a mediocre antiseptic with mod residual according to the FDA research. So the highest kill claims are CHG & Alcohol and the hughest residual is CHG & alcohol. If furture reserach identifies a beter product or comination, let's embrace that one THEN, but for now let's embrace what we know works. |
| 21 | Sandra Neri, SMCS | Justification | Both DuraPrep and ChloraPrep in our facility are the most utilized prep products. At our facility it is still an MD choice for the chosen product. Most of our surgeons who were using DuraPrep have switched to ChloraPrep, they like the 48 hour kill factor for bacterial growth. Some groups have made the decision to swith solely to ChloraPrep - OBGYN, Ortho, and for all Central Line Placements by Infection Control. |
| 25 | Brenda Helms, BHCS | Justification | There are numerous studies stating that 2% CHG and 70% alcohol are the most effective in preventing infections. The recent study was not a randomized control study and so I don't feel that it is a study that can truly be compared with a study that is. |

| # | Organization Contact | Topic | Comment |
|---|---|---------------|--|
| 2 | 7 Susan Tolentino, Holy Cross Hospital | Justification | We have chosen to convert to 2% chlorhexdine and 70%IPA because of the evidence out there right now. The SSI study done in the New Englad Journal proved a 41% reduction in SSI's compared to betadine. The problem with products that have betdine is that iodine can be neutralized in the presence of blood and organic matter. It is also not as broad spectrum as chlorhexidine. Our facility has had great success with Chloraprep. |
| 2 | Janee Macklin, McLaren Health Care | Justification | Dear NQF Reviewers, While I can appreciate 3M's concern due to potential market share & financial loss to their company I encourage you to not be confused by their half truths and misleading information that is presented in their request. If you do choose to entertain their comments please ask them to provide clinical studies that document the safety of PVP-I solutions related to meninges. No such studies exist for any skin prep. There are however sufficient studies published that demonstrate the superiority of CHG/IPA solutions over PVP-I solutions in a variety of patient settings. Please consider the many documented successes and potential lives saved from the implementation of CHG/IPA solutions. Do not allow yourselves to become side tracked with deceptive illusions portrayed by for-profit companies who are attempting to manipulate you in order to minimize their own financial loss that they may experience by you doing the right thing to protect the patients in this country. |

| # | Organization Contact | Topic | Comment |
|----|---|-------|---|
| 31 | Kathleen Kohut, Independent Consultant | | Surgical preps have not been well studied and the recent evidence cited is insufficient to allow for such a prescriptive perspective by the NQF. All of the three most recent studies are flawed in some manner: Example #1- Saltzman, MD, et al. Efficacy of Surgical Preparation Solutions in Shoulder Surgery. J Bone Joint Surg AM 2009;91:1949053 is a microbial count study with a sample size of 150 patients. The comparison between the prep solutions determined that microbial counts were less when the CHG product was used. However, the SSI outcomes for these patients was of no statistical significance. The correlation between microbial counts and SSI outcomes has not been established and therefore a poor proxy for analysis. Example #2 -Swenson, et al. Preoperative skin preparation on postoperative wound infection: a prospective study of three skin preparation protocols. Infect Control Hosp Epidemiol 2009; 30:964-971. This study was not randomized but did compare three preps solutions and utilized SSI outcomes as the endpoint. The results demonstrated that of the 3200 patients, the iodophor based skin preps had lower SSI rates than the CHG product in certain categories. The researchers concluded that more research is warranted prior to making any strong conclusions regarding surgical skin preps. |

| | Ourse starting | | |
|----|---|---------------|--|
| | Organization Contact | Topic | Comment |
| 32 | Kathleen Kohut, Independent Consultant | Justification | The most recent study of surgical preps was published in 2010. Darouiche, RO, et al. Chlorhexidine- Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med 2010; 362(1):18-26 is a comparison between iodophor scrub and paint and a CHG/alcohol product. The CHG/alcohol product demonstrated significant SSI reductions in some categories. However, it is common knowledge that surgical skin preps that contain alcohol outperform preps without alcohol due to the superior kill factor of alcohol. This study should be repeated comparing iodophor/alcohol products to CHG/alcohol products to really understand the efficacy of each. In addition to the efficacy of the prepping solutions the ease of application may be a significant factor between surgical skin preps. Surgical preps that must be scrubbed onto the skin are much more difficult to apply as compared to painted products. In my own observations of product usage, the products requiring scrubbing techniques are rarely applied according to manufacturer's directions and therefore, pose a safety risk to patients who are not benefiting from the proper application and efficacy of the product. Body surfaces must also be taken into consideration as certain surgical sites are contraindicated with CHG based products. There is not "one size fits all" evidence to warrant the advocacy of CHG skin prepping solutions over other FDA approved surgical skin prep solutions. |
| 34 | Ed Septimus, HCA | Justification | I agrre with the concerns discussed in letter by 3M The literature currently does not clealry favor one alcohol prep over another further trials will need to be done |
| 36 | Richard Raffule, Kaleida Health | Justification | I am writing this as a member of a core team that has been tasked with decreasing the post-op infection rate for our organization, which is made up of 5 hospitals. Our doctors, nurses, and infection control team has weighed the evidence of past studies and the most recent studies concerning CHG and alcohol compared to iodine and alcohol. Based on the evidence, and results we have achieved already with CHG and alcohol products, we have found that CHG and alcohol provides our patients with the best protection in preventing surgical site infections. Our clinical team has been impressed with the results that CHG and alcohol products have provided for our patients. |
| | Troy Thurmond, St. Vincent's | Justification | I would like to see a true study of Chloraprep vs DuraPrep |
| | Medical Center | N | NOF DRAFT: DO NOT CITE, QUOTE, REPRODUCE, OR CIRCULATE |

| # | Organization Contact | Topic | Comment |
|----|---|---------------|--|
| 52 | Amy Whisnant, CVMC | Justification | Our postoperative infections dropped considerably after implementing Chlora Prep. |
| 54 | Paul Durgan, St. Vincent Hospital | Justification | This is clearly a company (3M) defending it's product. There are multiple studies available that have compared CHG based preps versus Iodine based preps and the evidence is out there - CHG based preps have a much better track record of reducing SSI as well as IV site infections. It's amazing that 3M promotes Duraprep for skin prep but Avagard for a Surgical Hand scrub. Avagard is CHG and alcohol! It has the longest residual effect which is why we use it! You can not change the evidence based on one study that was not done on a randomized basis. The overwhelming evidence that CHG based preps have better outcomes speaks for itself. |
| 56 | Margaret Mulcrone, Henry Ford West Bloomfield Hospital | Justification | Chloraprep is a good product. My hospital converted over to chloraprep based on Safe Practice 22 statement. The only problem we had initially is teaching the staff to apply the chloraprep as recommended. SSI rate is low to none. If we had problems with post-op infections relating to surgery it was usually caused by incorrect application of product. However, I have to agree with the justification for review. More studies needs to done on Chloraprep vs. Duraprep. I think you are going to find both provide superior skin aseptic qualities. Also, it is very difficult to recommend one skin antiseptic product when the skin antiseptic product has limitations to where it can be applied. Another issue is cost. Chloraprep is at least double the cost of Duraprep. It would be great to be have choices. |
| 59 | Laura Larson, Tanner Health System | Justification | I feel that NQF SP22 should remain as it is. Good evidence supports CHG over PI at this time. In the future, if studies support Duraprep as well, then the SP22 could be amended to include Duraprep. We need to go with what evidence-based practice dictates to do at this time. |
| 60 | Claudine DeFreytas, Huntington Hospital | Justification | I believe that the MQS safe practice Number 22 should stay the way it is written in favor of the 2% chlorhexadine in 70% alcohol for a surgical site prep. There is evidence that the 2% chlorhexadine in 70% alcohol is superior and we use it as our prep of choice. |
| 62 | Paul Kearney, UKHealthcare | Justification | Not a bad argument but must there must be balance realizing that 3M has a proprietary interest in the success of their product in the Market. |

| # | Organization Contact | Topic | Comment |
|----|---|---------------|---|
| 64 | javad Parvizi, Rothman Institute | Justification | As a joint surgeon with special interest in periprosthetic joint infection, I endorse the notion that there is insufficient evidence to support the use of a single skin preparation. It would therefore be prudent for the NQF, as recommended by the expert panel, to avoid being prescriptive in their recommendations. Iodine combined with alcohol has been used at my instituion as the skin preparation of choice for over 30 years leading to SSI rate that is well below the national average, even in high risk patients. I agree with the concern raised by 3M in that some of the studies evaluating SSI that have demonstrated superiority of one prep over another had major methodological flaw and should not for the basis for recommending a single prep. I believe efforts to minimize SSI in our patients should intensify as th eburden presented by this dreaded complication is on the rise. Conducting well designed and unbiased studies are the steps in right direction. |
| 68 | Molly McBrayer, Roper St. Francis Healthcare | Justification | 3M is requesting the removal of a product-specific item being listed in the recommendation because it is not their product. Rather than accepting that the CHG-alcohol product is a superior product with a focus on quality patient care in the reduction of surgical site infections, 3M is focused on revenue. I strongly recommend that the CHG-alcohol product remain the recommendation for those surgical procedures in which it may safely be used for skin preparation. |
| 81 | Stephen Lewis, CareFusion | Justification | We agree that recent evidence regarding use of 2% chlorhexidine gluconate and isopropyl alcohol (CHG) did need to be reviewed given that published work that followed the original proposed text in SP22 is relevant. Two studies are critical. One by Swenson et al (October 2009 ICHE) was a weakly-controlled study that found lower surgical site infection (SSI) rates in the combined povidone-iodine & iodine-povacrylex group than CHG. The other was a multicenter randomized prospective trial published by Darouiche (January 2010 NEJM) that clearly favors the use of CHG over povidone-iodine. This is not the first time where a properly controlled studies. The NEJM editorial by Wenzel accompanying the Darouiche paper stated "the weight of evidence suggests that chlorhexidine-alcohol should replace povidone-iodine as the standard for preoperative surgical scrubs." We submit that SP22 in its original form overstated recommended practice and that it should be amended to reflect current best evidence to read: In clean-contaminated surgical cases, use chlorhexidine gluconate 2% and isopropyl alcohol solution preoperatively as the skin antiseptic preparation when not contraindicated. (See submitted supportive document CareFusion_SP22_Response) |

| # | Organization Contact | Торіс | Comment |
|----|-----------------------------------|---------------|---|
| 82 | Stephen Lewis, CareFusion | Justification | At least some factions within 3M may not have shared the view that review was necessary. In the expert comments, reviewer #3 commented that the concerns regarding Safe Practice 22 were raised by 3M as "makers of a competing product." However, 3M also makes the same product, chlorhexidine gluconate 2% and isopropyl alcohol but the 3M product is only licensed in Canada and has not received FDA approval in the U.S. Their own advertising in Canada (see figure 1 in the attached supporting document CareFusion_SP22_Response) that presents 3M as "CHG Experts" directly quotes the Darouiche paper stating that "preoperative skin cleaning with chlorhexidine-alcohol better protects against infection than povidone-iodine." |
| 88 | Rebecca Zimmermann, AHIP | Justification | AHIP appreciates the opportunity to provide comments on the Ad Hoc review of Safe Practice #22, Surgical Site Infection. Given the currently available evidence, the inclusion of chlorhexidine gluconate 2% and isopropyl alcohol solution in the Safe Practice appears to be overly prescriptive. We support a revision to Safe Practice #22 to recommend appropriate perioperative skin preparation and removal of language supporting one specific technique of skin preparation. |
| 6 | Nancy Moureau, PICC Excellence | Assessment | 39 different studies/reports support the Chlorhexidine gluconate as a highly effective skin disinfectant with residual qualities that promote safety in reduction of infection. As quoted by the Agency for Healthcare Quality and Research "Strict adherence to infection control methods, such as engaging in proper handwashing, using maximum barrier precautions, and using chlorhexidine gluconate antiseptic instead of betadine during catheter placement can reduce central line infection rates significantly.3 The Centers for Disease Control have long recommended Chlorhexidine as the preferred agent for skin preparation with the statement: Cutaneous antisepsis: Disinfect clean skin with an appropriate antiseptic before catheter insertion and during dressing changes. Although a 2% chlorhexidine-based preparation is preferred, tincture of iodine, an iodophor, or 70% alcohol can be used. (CDC/MMWR, 2002). With the drafted form of the 2010 recommendations the preference for Chlorhexidine provides a long lasting residual action against bacteria, lasting 48 hours or more. Chlorhexidine is considered the preferred agent for skin disinfection by CDC, Infectious Disease Society of America (IDSA) and The Society for Healthcare Epidemiology of America. I would hope that you would consider listing Chlorhexidine Gluconate with alcohol as the preferred agent for surgical site skin disinfection. |

| # | Organization Contact | Topic | Comment |
|----|--|------------|--|
| 8 | Nancy Moureau, PICC Excellence | Assessment | One Stop Guide to Surgical Preps: www.outpatientsurgery.net April/May 2010 Choose chlorhexidine as your default skin prep. Chlorhexidine gluconate, or CHG, is known for its relatively fast microbial kill, but it has another characteristic that is not as widely known. Its killing action against micro-organisms remains active much longer than with alcohol, povidone-iodine, or parachlorometaxylenol (PCMX). Chlorhexidine works by disrupting the cell membrane of bacteria. The CDC rates chlorhexidine as excellent against gram-negative bacteria such as Escherichia coli and salmonella, and good against gram-positive bacteria such as Clostridium difficile, Enterococcus and Staphylococcus aureus, which are the cause of 20% to 30% of surgical site infections, according to the Centers for Disease Control. Chlorhexidine has limited effectiveness against viruses, tuberculosis and fungi, but when combined with 70% alcohol the speed and effectiveness of action increases. Additionally, chlorhexidine is not deactivated when it comes into contact with blood making it an effective killing agent during surgical procedures. In addition to rating how well a skin prep kills bacteria initially, its residual effective kill time should also be considered in terms of as important or even of greater importance depending on the application. Ideally, residual activity of a prepping agent should continue for 48 hours or more as is the case with chlorhexidine. |
| 11 | Kathy Lemmon, DuBois Regional Medical Center | Assessment | As Director of Infection Control, I know without doubt, that use of CHG products have a significant positive impact on infection reduction. We currently daily bathe our ICU patients with a CHG product. Since implementation of this practice, we have had zero VAPs (ventilator-associated pneumonias), and zero catheter-associated urinary tract infections. |
| 14 | nikolaus gravenstein, university of florida college of medicine | Assessment | Clearly more studies are desirable as concluded by the panel. There is no compelling panel opinion to not still conclude that chlorhexidine alcohol is the preferred skin antiseptic. If future data show otherwise or demonstrate equivalent or better efficacy than chlorhexidine alcohol then the Safe Practice 22 language should of course be modified accordingly as information accumulates, but current best evidence and practice favors chlorhexidine alcohol as still being at least the preferred solution. |
| 16 | Karen Dominguez, St. Vincent's Medical Center | | Our facility has been using CHG products increasingly over the past few years to reduce bloodstream infections, surgical site infections, and contaminants when drawing blood cultures. We have seen a decrease in central line-associated bloodstream infections since we added ChloraPrep to our insertion bundles. As an Infection Preventionist, I advocate for our surgeons to use ChloraPrep as the standard for preventing SSI and have recently witnessed a decrease in SSI after several surgeons switched to using ChloraPrep. I agree with Expert #3's response; while there could always be more evidence to use CHG-alcohol for all sites, I have witnessed the success and support the use of ChloraPrep. QF DRAFT: DO NOT CITE, QUOTE, REPRODUCE, OR CIRCULATE |

| # | Organization Contact | Topic | Comment |
|----|---|------------|--|
| 17 | Marti Phelps, St. Vincent's Medical Center | Assessment | CHG products have been integral to our facility's reduction of Central Line, Blood Stream, UTI, and Surgical Site Infections in the last several years. In particular, the use of ChloraPrep has made a great impact on the reduction of the SSI rates. As an Infection Preventionist, and based on our facility's results, I advocate the use of this product as a surgical prep. |
| 19 | Teresa Smith, Methodist Hospitals of Memphis | Assessment | I can only speak personally (not to represent system position); however, NQF's Technical Expert #3 got it right (IMHO), i.e.,"if it isn't broken, don't fix it". Until convincing evidence from randomized controlled clinical trials in sizeable samples changes my mind, I will continue to support CHG for surgical skin preps (w/no involvement of meninges/mucous membranes). |
| 20 | gail rudder, sentara careplex hospital | Assessment | I agree that there needs to be supportive not suggestive documentation to show that there is comparability between the CHG/isopropyl alcohol skin prep and an iodine/alcohol prep. CHG as a skin prep prior to surgical and invasive procedures has been proven and supported by the CDC, SHEA and IDSA. 3M has a vested interest in posing these requests for consideration, however, I disagree that there should be a revision of any recommendation which supports evidenced based research. |
| 22 | Sandra Neri, SMCS | Assessment | The effectiveness of ChloraPrep seems to have great results if application is done according to manufacturer directions. I will be interested in reading further research done to support the use of ChloraPrep over other prep methods. Truly with Infection Control "strongly" enforcing the use of a 2% Chlorhexidine with alcohol, to be used as the prep of choice on all Central Line Placement procedures and with strict adherence to sterile technique, the results have been strong. |

| | Organization | m 1 | |
|---------|---|--------------------------|--|
| # 2: | Robbie Singer, Sutter Medical Center, Sacramento | Topic Assessment | Comment We recently switched from utilizing DuraPrep solution to ChloraPrep solution for all of our cesarean section surgery preps based on recent studies that have been published. We have found the ChloraPrep solution to be advantageous for a number of reasons including that the CHG solution does not require any removal other than soap & water post surgery. DuraPrep required the application of a special lotion to remove the dried prep solution from the patient's skin post-op. This extra lotion (and associated costs) had been routinely requested by our physicians and patients prepped with DuraPrep due to the discomfort of the dried, extremely sticky solution post- operatively. Another factor we were interested in is the duration of the sustained antimicrobial activity which we believe to be longer with ChloraPrep, especially since we do not remove the solution as we had with the DuraPrep. We have not had any incidence of surgical site infections since we have made the switch to ChloraPrep in our department. Whereas, last year we had 7 reported cases total with DuraPrep. Of course, there could be many other variables other than the surgical prep solution at work here. For example, when we switched over to utilizing ChloraPrep, we reinserviced all staff to the principles of surgical skin prep and required return demonstrations. Our procedure was totally rewritten and updated to current AORN standards. |

| # | Organization Contact | Topic | Comment |
|----|---|------------|---|
| 24 | Michelle Stevens, 3M Healthcare Business | Assessment | Response to reviewer 3 on other factors that could have influenced the SSI results from univariate analysis of the non-randomized Swenson study In addition to the univariate SSI analyses by study period (Table 2) and by actual prep used (Table 4), a multivariate analysis (logistic regression) was also performed, which included all the variables with a significant association with SSI (Table 3).This multivariate analysis (Table 5) resulted in a SSI odds ratio for the CHG/alcohol prep of 1.35, (95% CI of 0.97-1.87, p=0.073).Although not significant at the 5% level, there was a strong trend towards higher SSI with CHG/alcohol prep since the odds of a SSI in this case were 35% higher than with iodophor/alcohol preps. In other words, in 95% of patients the chance of having a SSI with CHG/alcohol ranged from 3% less to 87% higher than with iodophor/alcohol.These statistics imply that CHG/alcohol prepped patients would have a higher chance for a SSI than iodophor/alcohol prepped patients. Unfortunately, the randomized study (Darouiche) did not use an iodophor/alcohol preps.In contrast, the compelling data from the multivariate analysis favoring iodophor/alcohol in the Swenson study is the only clinical outcome study comparing iodophor/alcohol to CHG/alcohol preps.Consequently, 3M does not agree with reviewer #3 on recommending the endorsement of SP22 at this time due to insufficient data. |
| 26 | Brenda Helms, BHCS | Assessment | I agree with Expert #3. The study cited by 3M was not a randomized control study and was not independent of the manufacturer of Duraprep. At my facility (Cardiovascular Surgical Hospital) we use only 2%CHG and 70% alcohol as a surgical skin prep. By log reduction of microbes on the skin the chance of the patient developing an infection are decreased. Our infection rates are minimal and we intend to stick with our prep. |

| # | Organization Contact | Topic | Comment |
|---|---|------------|--|
| | 9 Janee Macklin, McLaren Health Care | Assessment | Dear NQF Reviewers, Regarding the recommendations of your ad hoc committee on Safe Practice 22, I see no reason for further delay in implementing your recommendation to endorse a CHG/IPA solution as the preferred & recommended pre-operative surgical skin prep. While further studies are always comforting they are also time consuming to complete. Upon reviewing the published data again I have confidence that you will not find them insufficient. We are at a time in our history where national healthcare reform and evidence based medicine is in the forefront due to the lives at stake. Timely decisions regarding best practice need to made with the information we have at present. I understand national guidelines & recommendations for best practice are not made lightly. However, please understand that healthcare institutions often will not act on their own without these national guidelines & set standards of care. With more government involvement and taxpayer dollars invested in healthcare there is a significant cost savings associated with infection prevention. There is no reason to believe that the same success that we have enjoyed in preventing blood stream infections will not also be experienced when you take a pro-active stand on behalf of vulnerable patients by affording them the same level of infection prevention when you make CHG/IPA solutions the prefered pre-operative skin prep. Thank you. |

| # | Organization Contact | Topic | Comment |
|----|-------------------------|------------|---|
| 30 | Gregg Bennett, 3M | Assessment | Response to reviewer 3 regarding 3M's support of a clinical study: Industry support was provided for all three clinical studies cited by reviewer 3 to varying degrees and by different manufacturers. The Darouiche study cited by reviewer 3 includes an industry author. As is well known, support of such clinical studies is common industry practice and helps advance patient safety and clinical science. 3M is supportive of such collaborations and believes in their value. Specific to the Swenson study, 3M's support in the form of an unrestricted educational grant was modest, and equivalent to less than \$10/patient studied. Additionally, 3M is not biased against CHG/alchohol preps and offers CHG/alcohol preps as part of our global product portfolio. It is our belief that clinicians are in the best position to choose the appropriate patient prepping protocol to meet the needs of their patients based on their interpretation of the available clinical evidence. Because CHG/alcohol preps are contraindicated for certain surgeries it is 3M's position that multiple effective preps should be recommended in any industry guideline. Consequently, 3M does not agree with reviewer #3 on recommending the endorsement of SP22. |
| 33 | Ed Septimus, HCA | Assessment | from available studies the best curent conclusion would be that an alcohol based prep is better than a non-alcohol based prep. Current literature is not conclusive whether alcohol/CHG is better than alcohol/iodophor therefore NQF should favor an alcohol based prep with either CHG or iodophor |

| # | Organization Contact | Topic | Comment |
|----|-------------------------|------------|---|
| 37 | Donna Jones, MADRI | Assessment | In conjunction with the recent annual conference of the Multidisciplinary Alliance Against Device- Related Infections (MADRI), an advisory panel comprising surgeons and infectious disease physicians held a meeting in Boston on June 3, 2010 to discuss the NQF Safe Practice Guideline #22 on prevention of surgical-site infections. Members of the advisory panel were selected and invited by MADRI which organized the meeting. The 10-member advisory panel included (in alphabetical order) Drs. David Berger, Rabih Darouiche, Donald Fry, Kamal Itani, John Mazuski, Robert Moellering, Lena Napolitano Joseph Solomkin, Robert Sherertz, and Sandra Torres. CareFusion provided educational funds to MADRI and had representatives present at the meeting. It was the opinion of this advisory panel that scientific evidence from published peer-reviewed studies that are listed below supports the role of chlorhexidine-alcohol as a superior agent for cleansing the skin before select types of surgery. A number of clinical studies over the past decade evaluated the efficacy of different antiseptic skin preparations in reducing skin flora. These studies support the efficacy of chlorhexidine. While reducing resident skin flora is important, two recent prospective randomized studies assessed the clinical outcome of surgical-site infection supported the notion that chlorhexidine-alcohol based preparations are more protective against infection than iodophor-based products without alcohol. |
| 38 | Donna Jones, MADRI | Assessment | Concerns were expressed regarding the generalizability of these two pivotal chlorhexidine-alcohol clinical outcome studies. (A) Published surgical studies that address the microbiologic impact of chlorhexidine-based vs. iodophors-based products include: (1) Bibbo, et al. Clin Orthop. 2005;438:204-8. A prospective randomized study of patients undergoing foot and ankle surgery reported significantly lower rates of culture-positive specimens in the chlorhexidine group than the iodophor group (38% vs. 79%; p=0.001). (2) Ostrander, et al. J Bone Joint Surg Am. 2005;87:980-985. A prospective randomized study of patients undergoing hallux and toe surgery indicated that the highest percentage of positive cultures occurred in the chloroxylenol group and the lowest percentage of positive cultures occurred in the chlorhexidine-alcohol group. It also demonstrated that the chlorhexidine-alcohol group (p<0.0001). (3) Saltzman, et al, J Bone Joint Surg Am. 2009;91:1949-53. A prospective single-institution study of patients undergoing shoulder surgery evaluated the efficacy of povidone iodine, povidone iodine-alcohol, and chlorhexidine-alcohol. Overall, the chlorhexidine-alcohol group had the lowest positive cultures (7%) as compared with iodophor group (31%; p<0.0001) and even the iodophor-alcohol group (19%; p=0.01). |

| # | Organization Contact | Topic | Comment |
|----|-------------------------|------------|--|
| 39 | Donna Jones, MADRI | Assessment | When considering only coagulase-negative staphylococci (most common isolate), both chlorhexidine- alcohol and iodophor-alcohol preparations were more effective than iodophor alone, but there was no significant difference between the two alcohol-based preparations. (B) Published prospective, randomized, clinical studies that support the superior protection afforded by chlorhexidine-alcohol based vs. iodophor-based antiseptic preparations in preventing surgical- site infection: (1) Paochareon, et al. J Med Assoc Thai. 2009;92:898-902. This prospective, randomized trial of patients undergoing general surgery showed that bacterial colonization at the incision site was significantly lower in the chlorhexidine-alcohol arm than in the iodophor arm (14.4% vs. 31.2%; 95% CI: 2.15-3.35). More importantly, the incidence of surgical-site infection at one month after surgery was significantly lower in the chlorhexidine arm than in the iodophor arm (2% vs. 3.2%; 95% CI = 1.40-1.81). (2) Darouiche, et al. N England J Med. 2010;362:18-26. This prospective, randomized, multi-center trial of patients undergoing clean-contaminated surgery demonstrated that the overall rate of surgical-site infection was significantly lower in patients whose skin was preoperatively cleansed with chlorhexidine-alcohol vs. povidone-iodine (9.5% vs. 16.1%; P=0.004). |
| 40 | Donna Jones, MADRI | Assessment | Not only did this large study yield a degree of reduction (41%) in the rate of surgical site infection in the chlorhexidine group that was comparable to that reported in the above study by Paochareon (38%), but it also expanded the applicability of this finding to both abdominal (colorectal, biliary, small intestinal, and gastroesophageal) and non-abdominal (thoracic, gynaecologic, urologic) clean-contaminated surgeries. The advisory panel also discussed the trial by Swenson, et al. Infect Control Hospital Epidemiology. 2009;30:964-71. This 3-group, cross-over, quasi-experimental, single-institution study was affected by a number of factors including differences in risk factors for infection between study groups, incomplete protocol application in each study period, unclear time as to when after surgery was surgical site infection assessed, and statistical grouping of iodophor and iodophor-alcohol groups for comparison with the chlorhexidine-alcohol group. These problems raise important concerns as to the reliability of the data and derived conclusions. The advisory panel believes that the body of scientific evidence supports a recommendation stating that chlorhexidine-alcohol preparation is preferable to povidone-iodine scrub and paint for preoperative cleansing of the skin in patients undergoing select clean-contaminated surgeries (level 1A evidence). |

| # | Organization Contact | Topic | Comment |
|----|-------------------------|------------|--|
| 41 | Donna Jones, MADRI | Assessment | As is the case with other types of antiseptic skin preparations, the use of chlorhexidine-alcohol preparation should adhere to the FDA-approved instructions of use in order to avoid toxicity and optimize efficacy. Because of the relatively low rate of surgical-site infection after clean surgery, it is unlikely that a sufficiently-powered, randomized, controlled trial would be performed to compare the efficacy of antiseptic preparations in patients undergoing clean surgery. The issue of whether the addition of alcohol to iodophor increases the efficacy of iodophor-based preoperative skin preparations was also considered. (C) Published studies that compared the efficacy of iodophor vs. iodophor-alcohol preparations: 1. Birnbach, et al. Anesthesiology. 2003;98:164-9. This prospective single-institution study compared the efficacy of povidone-iodine vs. an iodophor- alcohol solution for skin disinfection prior to epidural catheter insertion in parturient patient population. The proportion of subjects with positive skin cultures immediately after skin disinfection was significantly higher in the povidone-iodine group vs. iodophor- alcohol group (30 vs. 3%, respectively, $P = 0.01$). |
| 42 | Donna Jones, MADRI | Assessment | The number of subjects with any positive skin cultures at the time of catheter removal was also greater in the povidone-iodine group than the iodophor- alcohol group (97 vs. 50%, respectively; P =0.0001), as was the number of colonies cultured from the skin (log CFU, 1.93 +/- 0.40 vs. 0.90 +/- 0.23, respectively; P = 0.03). 2. Boston, et al. Infect Control Hospital Epidemiology. 2009;30:884-889. This case-control study examined patient- and hospital-associated risk factors for surgical-site infection by using existing data on patients who underwent spinal operations. Multivariable analysis using logistic regression analysis showed that preoperative skin antisepsis with only povidone iodine, instead of iodine and iodophor-alcohol, was more protective against surgical-site infection (OR, 0.16; 95% CI, 0.06-0.45). 3. Segal, et al. AORNJ. 2002;76:821–8. This randomized study evaluated the effect of four different preoperative skin preparations on wound infection rates in patients undergoing open heart surgery. Patients received one of the four following skin preparations: povidone-iodine paint, povidone-iodine 5-minute scrub with paint, one-step Iodophor-alcohol water insoluble film, and one-step Iodophor-alcohol water insoluble film with iodine-impregnated incise drape. Although fewer infections occurred in the one-step Iodophor-alcohol water insoluble film group, the study was underpowered to detect real differences. |

| # | Organization Contact | Topic | Comment |
|----|-------------------------|------------|---|
| 43 | Donna Jones, MADRI | Assessment | 4. Alexander, et al. Arch Surg. 1985;120:1357–61. This study compared three different preoperative scrubs: a 1-minute scrub using 70% alcohol, a 1-minute scrub using 2% iodine in 90% alcohol, and a 10-minute iodine soap scrub followed by iodine paint. Similar rates of surgical-site infection were reported in the three groups. 5. Lorenz, et al. J Reprod Med. 1988;33:202–4. This study compared a 5-minute Iodophor scrub with a 1-minute isopropyl alcohol scrub and an Iodophor antimicrobial drape. The two study groups had similar rates of surgical-site infection. 6. Kothuis et al. Neth J Surg. 1981;33186–9. This study evaluated the effect of povidone-iodine vs. alcohol plus iodine tincture in patients undergoing elective laparotomy. The wound sepsis rate was 16% in the povidone-iodine group vs. 13% in the alcohol-iodine group. The investigators concluded that the two studied antiseptic preparations were comparable. 7. Gilliam, et al. Clin Orthop. 1990;250:258–60. This randomized study compared the efficacy of an iodophor 5-minute scrub-and-paint vs. a single application of a water insoluble Iodophor-alcohol solution in patients undergoing clean total joint surgery. The skin of each patient was cultured before applying the antiseptic preparation and before wound closure. The two studied preparations were equally effective in reducing the number of bacteria on the skin. |
| 44 | Donna Jones, MADRI | Assessment | . 8. Hort, et al. Foot Ankle Int. 2002;23(10): 946–8. This randomized study investigated the effects of a standard povidone-iodine skin preparation with and without alcohol. Patients received either a 10-minute scrub with povidone-iodine followed by skin painting with povidone- iodine or the same procedure with the addition of a 3-minute preoperative preparation with 70% alcohol. Culture swabs were obtained immediately after skin preparation. Cultures were positive in 35% of patients receiving the standard preparation and in 57% of patients receiving the standard preparation and in 57% of patients receiving the standard preparation plus alcohol. No patients had clinical evidence of infection or wound problems. The investigators concluded that the inclusion of alcohol provided no additional benefit in the prevention of surgical-site contamination. Although the trial by Birnbach and colleagues (study #1) showed that iodophor-alcohol is superior to iodophor alone in reducing contamination of the skin and the epidural catheter, this study did not assess the clinical outcome of infection and was not a surgical study. The seven listed surgical studies collectively indicated that iodophor-alcohol is not superior to iodophor alone in preventing surgical-site infection (studies #2, 3, 4, 5 and 6) or reducing microbiologic contamination (studies #7 and 8). |
| 45 | Donna Jones, MADRI | Assessment | Taking into consideration that some of these studies were underpowered and had important methodological limitations, we found no clear evidence that iodophor-alcohol is superior to iodophor alone for preoperative cleansing of the skin. The advisory panel believes that this issue cannot be fully resolved without a well-designed comparative clinical outcome trial. |

| # | Organization Contact | Topic | Comment |
|----|--|------------|---|
| 46 | Inmaculada Soria, 3M | Assessment | SwensonBR,SawyerRG.Importance of Alcohol in Skin Preparation Protocols.Infect Control Hosp Epidem 2010;31(9) http://www.ncbi.nlm.nih.gov/pubmed/20636130 Main points from this correspondence: •Darouiche study showed that patients prepared with CHG/alcohol have lower SSI rates than with aqueous iodophor (no alcohol) •Swenson study showed that patients prepared with iodophor/alcohol have lower SSI rates than with CHG/alcohol •SSI rate for CHG/alcohol prepared patients undergoing clean-contaminated surgeries was similar in both studies (Darouiche 39/409-9.5% and Swenson 46/454-10.1%) •Alcohol,with its rapid bactericidal activity,may be a critical component of the iodophor preps •Darouiche study is limited by the exclusion of alcohol in the iodophor group •There is agreement that,based on the Darouiche results,the use of iodophor (no alcohol) should be abandoned •There is a clear need for additional experimental data comparing SSI rates between CHG/alcohol and iodophor/alcohol preps, before the question of whether one or the other is superior can be answered Randomized,controlled studies (RCT) and well designed observational studies are important tools in clinical research.The results of a single RCT or observational study should be interpreted with caution1 since further investigation is needed before recommending application of the findings.At this time there is not enough clinical evidence to support a single skin prep 1Concato J et al.N Eng J Med 2000,342:1887-1892 |
| 49 | Laura Haskins, Memphis Midsouth OB-GYN Alliance | Assessment | Over the last several years I have used 2% chlorhexidine with 70% isopropyl alcohol on my surgical patients with outstanding clinical outcomes. It is the best surgical prep available. I highly recommend adopting safe practice 22 as written. |
| 51 | Troy Thurmond, St. Vincent's Medical Center | Assessment | I agree that I would support liquid CHG over liquid betadine for a surgical prep. The prime reason is CHG does not have to wait to dry to begin killing action. Also the presence of blood, breaks down betadine liquid. |
| | Lyn Tipton, Huntsville Hospital | Assessment | Infection Prevention @ our Organization beieves the 2% CHG with 70% IPA is the best and has the best literature that shows this. |
| 55 | Paul Durgan, St. Vincent Hospital | Assessment | I agree that the statement should remain as is. If there new evidence that becomes available, the statement can be revised as indicated. For now, the evidence supports the use of CHG. |

| | Organization Contact | Topic | Comment |
|----|---|------------|--|
| 57 | Margaret Mulcrone, Henry Ford West Bloomfield Hospital | Assessment | I do not agree with the final assessment. I think recommending one skin antiseptic product is very limited and does not meet every aspect/area of skin prepping. SP 22 should not recommend one product but instead all products and where they best serve. I think that all skin prep products possess acceptable qualities when used correctly. |
| 58 | Michelle Flood, APIC-GD | Assessment | I support the recommendation of using a skin prep with CHG and alcohol. Currently there are more well done studies that support the use of this skin prep over the alternatives. |
| 61 | Claudine DeFreytas, Huntington Hospital | Assessment | As an Infection Control Professional ,I agree with the # 3 expert that states there is overwhelming evidence of the superior effectiveness of 2% CHG and 70% alcohol |
| 63 | Paul Kearney, UKHealthcare | Assessment | There is absolutely no question that Chlorhexidine/alcolol is superior to povidone-iodine preps. The real question is whether glue based povidone-iodine-alcohol are equivalent to CHG-alcohol. The latter is a better antiseptic, it has dermal absorption. As a consequence antisepsis continues even when the surface layer is washed off. |
| 65 | Marc Chavez, Kootenai Medical Center | | I agree with technical expert #3. The overwhelming amount of evidence suggests that 2% CHG/70% IPA should replace Povidone-Iodine as the new standard for surgical-site antisepsis for appropriate surgical procedures. I have yet to find a well designed study that proves DuraPrep to be more protective than PVP. Since PVP is still the most widely used surgical skin prep, it only makes sense to create a new standard of care if a product has been proven significantly superior through well controlled, multicenter, randomized studies. Data generated from non-randomized studies, i.e. the Swenson study, should not be assessed as evidence and the author himself states, "The current study has limitations that will prevent widespread application of its findings." This study did not control multiple risk factors that affect infection. Also, compliance in regards to the assigned skin prep was only 70% at best, yet all infections were attributed to the period groups assigned. We need to take the prevention of surgical site infections seriously and let the weight of high quality evidence rule our decision in making new recommendations. |

| | Organization Contact | Торіс | Comment |
|----|---|------------|---|
| 66 | Bernard Rosenfeld, Women's Hospital of Texas | Assessment | As a surgeon, I agree completely the evidence based medicine risk benefit ratio should demand the CHG-alcohol should replace povidone-iodine preoperative routine skin antisepsis. As a surgeon we depend on our colleagues in the Infection disease Department to recommend best preoperative practices to prevent surgical site infections. I agree completely with Dr. Dickema wrote in Journal Watch Infectious diseases. That CHG- alcohol which is about preferred for skin preparation before I.V. Catheter placement should now replace povidone-iodine for preoperative skin asepsis. CHG- alcohol should now be standard of care. A future 4 year prospective study to compare CHG- alcohol to povidone-iodine would be unethical as the povidone-iodine group would need to be informed that there is only and 4 in 1000 chance (p0.004) that CHG-ALCOHOL does not prevent surgical site infections better than povidone-iodine. All of the hospitals in the Texas Medical Center have now replaced povidone-iodine with CHG-alcohol as the standard preoperative scrub when appropriate. My nursing staff has conducted a phone survey to 65 of the largest United States hospitals Infectious Disease Departments and found over 20 % have recently switched to CHG-alcohol since the New England Journal article was published. It is obvious that they would not have switched to this new costly skin preparation if they reviewed the evidence and felt this was the correct action. |
| 67 | Donna Seidel, Orlando Health | Assessment | GYN OR changed to CHG/alcohol prep as part of a care "bundle" with a resulting surgical site infection rate of <1% |
| 69 | Molly McBrayer, Roper St. Francis Healthcare | Assessment | CHG-alcohol skin preparation is a superior product with proven efficacy in reducing surgical site infections. With a log reduction of 48+ hours, the CHG-alcohol product outpreforms the iodine- alcohol product in persisence for resident bacteria. I personally have requested CHG-alcohol skin preparation for myself and my family as well as my patients. If able to use an acohol-based product for a specific surgical procedure, I recommend CHG-alcohol tincture product. In those procedures in which CHG should not be used, such as with any potential contact with meninges, the iodine- alcohol product is superior rather than iodine-based without the tincture alcohol. |
| 70 | Ary Habig, Gulf Breeze Hospital | Assessment | CHG is persistent activity after application, iodine based products do not. |
| | Ary Habig, Gulf Breeze Hospital | Assessment | CHG is effective in the prescence of blood, iodine based products are not. |
| 72 | Ary Habig, Gulf Breeze Hospital | Assessment | CHG is persistent activity after application, iodine based products do not. |

| # | Organization Contact | Topic | Comment |
|----|--|------------|--|
| 74 | Bernard Rosenfeld, Women's Hospital of Texas | Assessment | The major concern about CHG-alcohol is that it is significantly more expensive that povidone- iodine. This is not true in July 2010. While the wholesale price of generic CGH-alcohol is \$54.99 the generic price of providone is \$55.79. This should not be a contest between representatives of 3M and Cardinal Health, but a broad scientific inquiry of the evidence. CHG-alcohol should replace povidone-iodine as the routine surgical scrub. |
| 75 | Tricia Kassab, City of Hope | Assessment | What is being challenged is a previous decision to use chlorhexidine gluconate 2% and isopropyl alcohol solution as the preferred preoperative skin preparation as part of Saafe Practice #22. What I understand we as NQF members are being asked to comment on is whether there is sufficient evidence to sustain the original decision. A majority of the technical experts concluded that the evidence was insufficient to determine whether one solution was superior to the other. Based on my review of the submitted evidence, I would agree with the majority opinion of the technical experts. I have no constructive comments to offer that were not already part of the technical experts review. From a data collection perspective, preoperative skin preparations are documented in our Nursing Intraoperative record under prep solutions. I believe that this document is printed from our SIS or surgery documentation system. There does not appear to be any documentation of the drying time. |
| 76 | Sherrie Mannarino, RoperSt.Francis Healthcare | Assessment | From my clinical perspective, the use of Chloraprep for prepping the surgical incision is valid and warranted. Although I do not have data at my fingertips, the incidence of surgical site infections among cardiac patients has dramatically been reduced since the inception of Chloraprep use. Additionally, the majority of orthopedic surgeons have converted from betadine to Chloraprep. This practice change has resulted in improved patient outcomes. |
| 77 | Neil Zaboy, ranciscan Health System | Assessment | Currently the best available evidence supports the use of CHG in many cases. Since CHG is a comparaelatively new product and has had to demonstrate safety, efficacy and effectiveness more recently, whereas iodine-alcohol and other formulations were grandfathered as an accepted practice, it would be prudent to put Iodine- alcohol and other products through a comparative accelerated new product or orphan drug type review. NPSG 22 should stand as written until additional comparable supporting evidence for other products is accepted and reviewed. |

| # | Organization Contact | Topic | Comment |
|----|---|------------|---|
| 78 | Rita Munley Gallagher, PhD, RN, American Nurses Association | Assessment | The American Nurses Association (ANA) concurs with the need for additional clinical study before the NQF Safe Practices can recommend one prep over another. It is ANA's understanding that both CHG-alcohol and iodine-based + alcohol solutions used for skin antisepsis have very similar properties. Therefore, ANA would support the recommendation that NQF not specify a particular agent, but instead emphasize the requirements for broad spectrum activity, rapid action, persistent/residual activity and safety both in patient application and environmental use. Given the dynamic nature of the Safe Practices, ANA respectfully suggests that NQF qualify the statement with the understanding that when new data are presented that show one product to be superior to all others a revised practice statement will be issued. |
| 79 | Stephen Lewis, CareFusion | Assessment | A justification for review is that "there is evidence that implementation of the measure in practice may result in inappropriate or harmful care. The evidence obtained from a randomized multicenter trial (Darouiche, NEJM Jan 2010) showed a 40% reduction in surgical site infection rates in clean-contaminated surgery with use of 2% chlorhexidine gluconate and isopropyl alcohol (CHG). Using the definitions for clean-contaminated surgery from the Darouiche study, we estimated the number of such cases in the nationwide sample contained in the 2007 AHRQ Healthcare Cost and Utilization Project data to be 2,085,981 such cases. The Darouiche study showed a 6.6% absolute SSI rate reduction favoring use of CHG. This translates into 137,675 preventable SSIs and 1,377 preventable deaths annually. An estimate of \$12,197 (Kilgore, Medical Care Jan 2008) for the incremental cost per HAI, suggests an annual potential cost saving to the healthcare system of \$1,679,218,877. A decision to strike mention of CHG in Safe Practice 22 while awaiting further prospective trials would expose clean-contaminated surgery patients in the U.S to needless risk. Hence, we propose amending it to read: In clean-contaminated surgical cases, use chlorhexidine gluconate 2% and isopropyl alcohol solution preoperatively as the skin antiseptic preparation when not contraindicated. (See submitted supportive document CareFusion_SP22_Response) |

| # | Organization Contact | Topic | Comment |
|----|---|------------|--|
| 80 | Stephen Lewis, CareFusion | Assessment | As part of the expert review, reviewer #3 commented that "recent excellent evidence, in the form of a randomized controlled clinical trial, has supported the use of CHG-alcohol as preferable to povidone-iodine in the context of general surgical cases, primarily abdominal." Reviewer 3 went on to comment on the methodological issues surrounding the Swenson study (Swenson ICHE October 2009) and concluded "the 3M group suggests that future studies may show the comparability of CHG alcohol to povidone iodine alcohol, however I am unmoved by this argument, since such a study, equal in quality to the Darouiche NEJM paper, has not been done. Since the SP is being analyzed at present, it seems logical to base the NQF recommendation on the current, good evidence available at present. If at some future date solid evidence becomes available supporting the 3M concern, the SP #22 could be revised at that time. I would leave SP22 as it is." This is strongly supportive of the original recommendation. Thus, we are surprised that in the face of a split decision and with evidence from a prospective trial, a decision to strike comment regarding CHG in SP 22 was made. We strongly suggest that rather than striking CHG in Safe Practice 22 it be amended to read: In clean-contaminated surgical cases, use chlorhexidine gluconate 2% and isopropyl alcohol solution preoperatively as the skin antiseptic preparation when not contraindicated. (See submitted supportive document CareFusion_SP22_Response |
| 83 | Arely Rego, Doctors Hospital, Baptist Health South Florida | Assessment | There is substantial evidence that supports the use of 2% chlorhexidine gluconate + 70% isopropyl alcohol as skin prep as opposed to iodine-based preps to prevent catheter-related blood stream infections. The Darouiche study is further evidence supporting the use of this combination in the OR. By implementing the 2% CHG + 70% IPA combination as the skin prep of choice in my facility, the incidence of catheter related blood stream infections has been reduced significantly. It is my belief that the same combination would also reduce surgical site infections in the OR, and should therefore be recommended in the NQF Safe Practices. |
| 84 | Rebecca Zimmermann, AHIP | Assessment | AHIP appreciates the opportunity to provide comments on the Ad Hoc review of Safe Practice #22, Surgical Site Infection. Given the currently available evidence, the inclusion of chlorhexidine gluconate 2% and isopropyl alcohol solution in the Safe Practice appears to be overly prescriptive. We support a revision to Safe Practice #22 to recommend appropriate perioperative skin preparation and removal of language supporting one specific technique of skin preparation. |

| | Organization | | |
|----|--|------------|--|
| # | Contact | Topic | Comment |
| 85 | Ron Walters, The University of Texas MD Anderson Cancer Center | Assessment | Based on the information presented, we agree that the recommended single approach (CHG 2% with isopropyl alcohol solution) for preoperative SSI prevention is inappropriate. First, the recommendation is to use isopropyl alcohol, which is flammable and has a warning label, instead of something that might be safer. The danger of flammability, while low, is real and profound and accordingly must be given due consideration. Additionally, CHG and alcohol are not appropriate for all surgical sites and applications. For example, CHG is contraindicated for use in or around the eyes, ears, mucous membranes or dura. Reports of blindness and deafness after contact in the eyes or ears have been reported. The head and neck is an area of high vascularity, and for clean cases the risk of an SSI is 1% or less. For clean-contaminated cases the risk is higher, but the source of wound contamination during surgery is from mucosally-based flora. Prophylactic antibiotics are used to target these organisms. Intuitively, skin flora are not a significant source of pathogens in these cases. |
| 86 | Ron Walters, The University of Texas MD Anderson Cancer Center | Assessment | The literature concerning surgical skin preparation is quite extensive comparing different combination of preps to different outcomes in various populations. The majority of studies compare "single" agents (chlorhexidine or povidone-iodine) against one of the alcohol combination preparations; of note, the studies show evidence which support the combination preparations. Rather than endorsing a single approach, NQF guidelines should support the evidence and state that skin preparations combined with alcohol have been shown to be more effective than single agent preparations in preventing surgical site infections. At this time, there are no controlled-randomized studies that compare the combination preparations of chlorhexidine-alcohol and iodine-alcohol. The Darouiche paper, being level-one evidence, only shows that CHG/alcohol is better than povidone-iodine. No data supports the non-use of other alcohol-containing preps. Therefore, there is insufficient evidence to support one combination skin preparation over another preparation. Prior to sweeping implementation as a general recommendation, the findings of the Darouiche study should be verified by follow-up studies since the data are not entirely clear for all surgical sites/applications of overwhelming superiority of one agent. |

| # | Organization Contact | Topic | Comment |
|---|--|-------|--|
| 8 | 7 Nancy H. Nielsen, MD, PhD, American Medical Association | | The American Medical Association (AMA) is pleased to have the opportunity to comment on the National Quality Forum's (NQF) Ad Hoc Review of Safe Practice 22, Surgical-site Infection Prevention. The AMA appreciates that NQF has put an ad hoc review process in place, and believes it is important to reassess safe practices, performance measures, and other recommendations that emerge from the work of NQF when new evidence becomes available. With respect to Safe Practice 22, the AMA also agrees with a less prescriptive safe practice approach allowing multiple antiseptic preparation agent options. It appears that the evidence-base is inconclusive and a more inclusive approach is appropriate at this point. However, we believe it is imperative that as new evidence becomes available this safe practice is reviewed once again. We appreciate the opportunity to comment on this report. |